LabGenomics Launches Rapid COVID-19 Diagnostic Kit

[Asia Economy Reporter Minji Lee] LabGenomics, a molecular diagnostic healthcare specialist company, announced on the 1st that it has launched the immune-diagnosis-based rapid COVID-19 test kit 'LabGun COVID-19 lgG/lgM' in collaboration with Kels.

The company has completed certifications such as the Ministry of Food and Drug Safety export item approval for domestic and international sales and CE-IVD, and plans to supply the product to the market promptly.

The rapid test kit launched by the company can diagnose with over 95% accuracy within 10 minutes using blood as the specimen. It tests the early antibodies formed in the body after viral infection, improving sensitivity by more than 100 times compared to existing rapid test kits, maintaining 95% accuracy for lgM (as early as 3 days after infection, usually around one week) and 97% accuracy for lgG (after 10 days of infection).

Since the rapid test kit enables quick on-site diagnosis, there is high demand for primary screening of unspecified infected individuals in large facilities such as airports and hospitals. Furthermore, the United States, China, and WHO also recommend using immunological antibody diagnosis through blood alongside molecular diagnostics, so demand is expected to continue steadily.

A company official stated, “The launch of the rapid test kit has been under consideration since the development stage of the PCR-based COVID-19 test kit,” adding, “During the negotiation process for purchasing PCR test kits, we confirmed the demand for rapid test kits, so we will create a synergy effect by leveraging our company's unique molecular diagnostic technology and immune diagnostic technology.”

The company developed a Real Time PCR-based COVID-19 test kit in February and is supplying it overseas.

This content was produced with the assistance of AI translation services.